iBio (NYSE:IBIO) Shares Down 1%

iBio, Inc. (NYSE:IBIO)’s stock price traded down 1% on Wednesday . The stock traded as low as $2.05 and last traded at $2.07. 124,709 shares traded hands during mid-day trading, a decline of 94% from the average session volume of 2,056,355 shares. The stock had previously closed at $2.09.

Analyst Upgrades and Downgrades

IBIO has been the topic of several research analyst reports. StockNews.com started coverage on shares of iBio in a research note on Saturday, April 20th. They set a “sell” rating on the stock. Chardan Capital reissued a “buy” rating and set a $5.00 price objective on shares of iBio in a research report on Monday, June 3rd.

iBio Stock Down 1.0 %

The business’s 50 day moving average is $2.11. The company has a quick ratio of 1.69, a current ratio of 1.69 and a debt-to-equity ratio of 0.04.

iBio (NYSE:IBIO) last issued its earnings results on Monday, May 13th. The company reported ($0.71) earnings per share (EPS) for the quarter. Equities research analysts expect that iBio, Inc. will post -99.82 EPS for the current fiscal year.

Hedge Funds Weigh In On iBio

Large investors have recently added to or reduced their stakes in the business. Ikarian Capital LLC bought a new position in shares of iBio during the first quarter valued at about $2,436,000. Opaleye Management Inc. bought a new stake in iBio in the first quarter worth about $2,761,000. Finally, Lynx1 Capital Management LP purchased a new position in iBio in the first quarter valued at about $2,436,000. Institutional investors own 7.90% of the company’s stock.

iBio Company Profile

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.